Breaking News

Particle Sciences, Actavis In Generic Drug Pact

April 2, 2014

Particle to provide design, formulation and cGMP supplies

Particle Sciences has entered into an exclusive agreement with Actavis plc to develop an undisclosed complex generic product. Particle Sciences is responsible for design, formulation and cGMP supplies, and will receive undisclosed milestone and revenue- based payments. Actavis will be responsible for clinical testing, regulatory filings and marketing. 
 
"We have worked with Actavis on a number of projects in the past," said Mark Mitchnick, Particle Sciences' chief executive officer. "This latest one leverages several of Particle Sciences core skillsets focused on sterile products with challenging formulation targets." 
 
"Over the past several years Particle Sciences has intentionally moved towards closer relationships with our clients by structuring our interactions to best align our respective goals," Mitchnick added. "This latest venture is a great example, and we are very pleased to have Actavis as our co-developer and marketer."

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems